Calcium score in the evaluation of atherosclerosis in patients with HIV/Aids

Arquivos Brasileiros de Cardiologia

Volumn 97, Issue 5, 2011, Pages 427-433

  Monteiro, Verônica Soares ^a,b   Lacerda, Heloisa Ramos ^a,d   Uellendahl, Marly ^a,c,e   Chang, Tien Man ^e   de Albuquerque, Valéria Maria ^a   Zirpoli, Josefina Cláudia ^d   Ximenes, Ricardo Arraes ^a,d   de Albuquerque, Maria de Fátima Militãeo ^f   Filho, Demócrito de Barros Miranda ^a   Filho, Dário Sobral ^a,e  

^a UNIVERSIDADE DE PERNAMBUCO   (Brazil)

^b INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e Pronto Socorro Cardiológico de Pernambuco PROCAPE   (Brazil)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Atherosclerosis blood; Calcium blood; Higly active adverse effects; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD EXAMINATION; CALCIUM SCORE; CARDIOVASCULAR RISK; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC DISORDER; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CALCINOSIS; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; REFERENCE VALUES; RISK FACTORS; SMOKING;

EID: 84455196235     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2011005000094     Document Type: Article

References (23)

1. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart. 2009;95(14):1193-202.
2. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005;118(Suppl 2):23S-28S.
3. Gasior Z, Pysz P, Dabek J. [A contemporary role of coronary artery calcium scoring in the assessment of the risk for coronary disease]. Pol Arch Med Wewn. 2007;117(3):91-4.
4. Escolar E, Weigold G, Fuisz A, Weissman N. New imaging techniques for diagnosing coronary artery disease. CMAJ. 2006;174(4):487-95.
5. Sociedade Brasileira de Cardiologia. Departamento de Cardiologia Clínica. Grupo de Estudos de Ressonância e Tomografia Cardiovascular (GERT). Guideline of Sociedade Brasileira de Cardiologia for ressonance and cardiovascular tomography. Executive Summary. Arq Bras Cardiol. 2006;87(supl 3):e1-12.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
8. Hu FB. Overweight and increased cardiovascular mortality: no French paradox. Hypertension. 2005;46(4):645-6.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52.
10. Kingsley LA, Cuervo-Rojas J, Muñoz A, Palella FJ, Post W, Witt MD, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. Aids. 2008;22(13):1589-99.
11. Talwani R, Falusi OM, Mendes de Leon CF, Nerad JL, Rich S, Proia LA, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30(2):191-5.
12. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart. 2009;95(22):1826-35.
13. Ho JS, Fitzgerald SJ, Stolfus LL, Wade WA, Reinhardt DB, Barlow CE, et al. Relation of a coronary artery calcium score higher than 400 to coronary stenoses detected using multidetector computed tomography and to traditional cardiovascular risk factors. Am J Cardiol. 2008;101(10):1444-7.
14. Hegele R, OH J. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infec Dis. 2007;7(12):787-96.
15. Kramer AS, Lazzarotto AS, Sprinz E, Manfroi WC. Alterações metabólicas, terapia antiretroviral e doença cardiovascular em idosos portadores de HIV. Arq Bras Cardiol. 2009;93(5):561-8.
16. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Higly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005;95(5):586-91.
17. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, et al. Carotid intimal medial thickness in Human Immunodeficiency Virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(12):4916-24.
18. Lai S, Lai H, Celentano DD, Vlahov D, Ren S, Margolick J, et al. Factors associated with accelerated atherosclerosis in HIV-1 infected persons treated with protease inhibitors. AIDS Patient Care STDS. 2003;17(5):211-9.
19. Colafigli M, Di Giambenedetto S, Bracciale L, Tamburrini E, Cauda R, De Luca A. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 2008;9(3):172-9.
20. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(Suppl 2):S79-85.
21. Sila EFR, Bassicheto KC, Lewi DS. Perfil lipídico, fatores de risco cardiovascular e síndrome metabólica em um grupo de pacientes com Aids. Arq Bras Cardiol. 2009;93(2):113-8.
22. Arruda Jr ER, Lacerda HR, Moura LCV, Albuquerque MFM, Miranda Filho DB, Diniz GTD, et al. Perfil dos pacientes com hipertensão arterial sistêmica incluídos em uma coorte com HIV/Aids em Pernambuco, Brasil. Arq Bras Cardiol. 2010;95(5):640-7.
23. Parra S, Coll B, Aragonés G, Marsillach J, Béltran R, Rull A, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med. 2010;11(4):225-31.